Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $139,860.00 in Stock

Posted by Brenda Bartman on Jul 10th, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the transaction, the insider owned 67,845 shares in the company, valued at $1,581,466.95. This trade represents a 8.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sharon Townson also recently made the following trade(s):

On Tuesday, June 23rd, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $60,000.00.
On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total value of $57,000.00.

Monte Rosa Therapeutics Price Performance

Shares of Monte Rosa Therapeutics stock opened at $24.52 on Friday. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -16.57 and a beta of 1.56. The stock has a 50-day simple moving average of $19.73 and a 200-day simple moving average of $19.11. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.12 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after acquiring an additional 257,547 shares during the last quarter. Strs Ohio bought a new position in shares of Monte Rosa Therapeutics during the 4th quarter valued at about $566,000. Massachusetts Financial Services Co. MA bought a new position in Monte Rosa Therapeutics in the fourth quarter valued at approximately $778,000. SG Americas Securities LLC lifted its position in Monte Rosa Therapeutics by 18.5% in the 1st quarter. SG Americas Securities LLC now owns 20,468 shares of the company’s stock valued at $337,000 after acquiring an additional 3,189 shares in the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth about $63,000. 79.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GLUE has been the topic of several analyst reports. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Guggenheim upped their target price on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Zacks Research downgraded Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday. Wells Fargo & Company decreased their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, JPMorgan Chase & Co. upped their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.33.

Read Our Latest Report on Monte Rosa Therapeutics

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.